CROP reports 78% five-year survival with SBRT and intermittent ADT in prostate cancer
In oligometastatic hormone-sensitive prostate cancer, comprehensive SBRT plus intermittent ADT produced 78.2% five-year survival and 15.2% failure-free survival.
In oligometastatic hormone-sensitive prostate cancer, comprehensive SBRT plus intermittent ADT produced 78.2% five-year survival and 15.2% failure-free survival.
In 27 interviews, patients described rushed radiotherapy decisions, limited discussion of declining treatment, and insufficient preparation for treatment-related effects.
In 203 patients with initially positive internal mammary nodes, doses above 60 Gy EQD2 did not improve five-year outcomes and increased dermatitis.
At 12 months, keloid recurrence was 6.9% with 13 Gy versus 23.3% with 9 Gy, but the overall randomized comparison was nonsignificant.
PREDICT achieved AUC 0.793 versus 0.749 for Roach in SEER, but its apparent advantage did not persist across external cohorts.
In 152 clinically node-positive breast cancer patients, 47.4% retained initially suspicious axillary nodes after dissection, with limited regional recurrence following RT.
In 452 stage III NSCLC patients, lower lung V1 was associated with subsequent immunotherapy initiation; an internally validated model achieved AUC 0.71.
In 222 patients with gastrointestinal cancer and CNS metastases, median survival was 3.7 months, while prognostic-score discrepancies exceeded three months in 32–55%.
A Japanese prospective registry reported 48.1% three-year overall survival and 5.2% grade ≥3 toxicity after proton or carbon-ion therapy for T3N0M0 NSCLC.
In 153 glioblastoma patients, combined 18F-DOPA PET and advanced MRI identified additional imaging-defined volumes beyond a 20-mm conventional MRI expansion in 20%.
In 260 vertebral metastases, GTV-based boosts showed lower Kaplan–Meier fracture estimates than segment-based boosts, but competing-risk analyses were inconclusive.
In 801 node-positive breast cancer patients, three-week comprehensive regional nodal IMRT showed similar overall acute toxicity and less grade ≥2 dermatitis.
A randomized study found no significant physical or mental quality-of-life improvement with weekly mobile symptom reporting during chemoradiotherapy.
Among 285 head and neck cancer patients, 28.4% had another primary cancer, leading to treatment modifications in 37% of affected patients.
In 473 pancreatic cancer patients, SBRT achieved 82% one-year local control, with higher biologically effective dose associated with better response.